JGJonas Graf

Jonas Graf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonas Graf has a total of 200 co-authors. Here are the top co-authors by number of shared publications:

  • Philipp Albrecht

    Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

    19 shared publications
  • Hans-Peter Hartung

    Department of Neurology, Medical Faculty, Heinrich-Heine University, 40225, Duesseldorf, Germany; Brain and Mind Center, University of Sydney, NSW, 2006, Australia; Department of Neurology, Medical University of Vienna, 1090, Vienna, Austria

    17 shared publications
  • Orhan Aktas

    Department of Neurology, Medical Faculty, University Hospital, Heinrich-Heine-University, 40225 Düsseldorf, Germany

    15 shared publications
  • Orhan Aktas

    Department of Neurology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, Germany

    14 shared publications
  • Hans-Peter Hartung

    Department of Neurology, Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany

    12 shared publications
  • Marius Ringelstein

    Düsseldorf, Germany)

    7 shared publications

Latest Publications

  • Open Access

    Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study

    by Jonas Graf, Huah Shin Ng, Feng Zhu, Yinshan Zhao, José Ma. Wijnands, Charity Evans, John D. Fisk, Ruth Ann Marrie, Helen Tremlett


  • Open Access

    Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits

    by Jonas Graf, Huah Shin Ng, Feng Zhu, Yinshan Zhao, José Ma Wijnands, Charity Evans, John D Fisk, Ruth Ann Marrie, Helen Tremlett

    We described emergency department (ED) visits (all visits and infection-related) by persons with multiple sclerosis (MS) in British Columbia, Canada (1 April 2012 to 31 December 2017). We identified 15,350 MS cases using health administrative data; 73.4% were women, averaging 51.4 years at study entry. Over 4.9 years of follow-up (mean), 56.0% of MS cases visited an ED (mean = 0.6 visits/person/year; total = 37,072 visits). A diagnosis was documented for 25,698 (69.3%) ED visits, and 18.4% (4725/25,698) were infection-related. Inpatient admissions were reported for 20.4% (5238/25,698) of all and 29.2% (1380/4725) of infection-related ED visits. Findings suggest that the ED plays a substantial role in MS healthcare and infection management.


  • Open Access

    The degree of cortical plasticity correlates with cognitive performance in patients with Multiple Sclerosis

    by Carolin Balloff, Iris-Katharina Penner, Meng Ma, Iason Georgiades, Lina Scala, Nina Troullinakis, Jonas Graf, David Kremer, Orhan Aktas, Hans-Peter Hartung, et al.


  • Open Access

    CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy

    by Jens Ingwersen, Jonas Graf, Julia Kluge, Margit Weise, Michael Dietrich, John-Ih Lee, Jens Harmel, Hans-Peter Hartung, Tobias Ruck, Sven G. Meuth, et al.

    Background and Objectives Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease primarily affecting the peripheral nervous system. However, several noncontrolled studies have suggested concomitant inflammatory CNS demyelination similar to multiple sclerosis. The aim of this study was to investigate an involvement of the visual pathway in patients with CIDP. Methods In this prospective cross-sectional study, we used high-resolution spectral-domain optical coherence tomography to compare the thickness of the peripapillary retinal nerve fiber layer and the deeper macular retinal layers as well as the total macular volume (TMV) in 22 patients with CIDP and 22 age-matched and sex-matched healthy control (HC) individuals. Retinal layers were semiautomatically segmented by the provided software and were correlated with clinical measures and nerve conduction studies. Results In patients with CIDP compared with healthy age-matched and sex-matched controls, we found slight but significant volume reductions of the ganglion cell/inner plexiform layer complex (CIDP 1.86 vs HC 1.95 mm3, p = 0.015), the retinal pigment epithelium (CIDP 0.38 vs HC 0.40 mm3, p = 0.02), and the TMV (CIDP 8.48 vs HC 8.75 mm3, p = 0.018). The ganglion cell layer volume and motor nerve conduction velocity were positively associated (B = 0.002, p = 0.02). Discussion Our data reveal subtle retinal neurodegeneration in patients with CIDP, providing evidence for visual pathway involvement, detectable by OCT. The results need corroboration in independent, larger cohorts.


  • Open Access

    Relapse-independent multiple sclerosis progression under natalizumab

    by Jonas Graf, Verena I Leussink, Giulia Soncin, Klaudia Lepka, Ingrid Meinl, Tania Kümpfel, Sven G Meuth, Hans-Peter Hartung, Joachim Havla, Orhan Aktas, et al.

    The objective of this study was to investigate confirmed progression independent of relapse activity in relapsing-remitting multiple sclerosis patients under long-term natalizumab treatment. We performed a retrospective, cross-sectional study of clinical data captured between 1994 and 2019 at two German multiple sclerosis tertiary referral centres. Data files of all relapsing-remitting multiple sclerosis patients treated with natalizumab for ≥24 months were analysed. Confirmed progression independent of relapse activity was defined as ≥12 week confirmed disability progression on a roving Expanded Disability Status Scale reference score by 1 point in patients with an Expanded Disability Status Scale score ≤3 or 0.5 in patients with an Expanded Disability Status Scale score ≥3.5 in the absence of a relapse. Cox proportional hazard models were used to analyse the probability of developing confirmed progression independent of relapse activity depending on both disease and natalizumab treatment duration. Among the 184 patients identified, 44 (24%) developed confirmed progression independent of relapse activity under natalizumab irrespective of the Expanded Disability Status Scale score at natalizumab onset. Time to confirmed progression independent of relapse activity was not affected by Expanded Disability Status Scale at natalizumab onset (categorized by Expanded Disability Status Scale score ≤3.5 versus >3.5) nor by duration of disease nor by duration of therapy. Confirmed progression independent of relapse activity occurred earlier in the disease course in patients with an earlier natalizumab therapy onset with regard to disease duration. A stepwise forward regression analysis revealed disease duration as the main factor for confirmed progression independent of relapse activity development (P = 0.005). Taken together, confirmed progression independent of relapse activity occurs in a substantial proportion of patients on long-term natalizumab treatment and independent of Expanded Disability Status Scale score at natalizumab onset. Our findings suggest that patients who are initiated on natalizumab early during disease course, usually in order to treat an aggressive clinical phenotype, have a higher risk of early confirmed progression independent of relapse activity.


  • Open Access

    Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis

    by Sharon Jean Baetge, Michael Dietrich, Melanie Filser, Alina Renner, Nathalie Stute, Marcia Gasis, Margit Weise, Klaudia Lepka, Jonas Graf, Norbert Goebels, et al.

    Objective Retinal layer thickness (RLT) measured by optical coherence tomography (OCT) is considered a noninvasive, cost-efficient marker of neurodegeneration in multiple sclerosis (MS). We aimed to investigate associations of RLT with cognitive performance and its potential as indicator of cognitive status in patients with MS by performing generalized estimating equation (GEE) analyses. Methods In this cross-sectional study, patients with at least mild signs of cognitive impairment were examined by OCT as well as by the Brief International Cognitive Assessment for MS and tests assessing attention and executive functions (Trail Making Test [TMT] A and B). Associations of these factors were investigated using GEE models controlling for demographic and disease-related factors and correcting for multiple testing. Results A total of 64 patients entered the study. In the final sample (n = 50 [n = 14 excluded due to missing data or drop-outs]; n = 44 relapsing-remitting MS and n = 6 secondary progressive MS, mean Expanded Disability Status Scale score = 2.59 [SD = 1.17], disease duration [median] = 7.34 [interquartile range = 12.1]), 36.0% were cognitively impaired. RLT of the macular retinal nerve fiber layer was associated with performance in TMT-B (β = −0.259). Analyses focusing on the upper and lower tertile of RLT additionally revealed associations between macular ganglion cell-inner plexiform layer and TMT-B and verbal short-term memory and learning, respectively. Conclusion In patients with MS, at less advanced disease stages, RLT was especially associated with cognitive flexibility promoting OCT as a potential marker advocating further extensive neuropsychological examination.


  • Open Access

    Targeting B Cells to Modify MS, NMOSD, and MOGAD

    by Jonas Graf, Jan Mares, Michael Barnett, Orhan Aktas, Philipp Albrecht, Scott S. Zamvil, Hans-Peter Hartung

    Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell–related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD), or are in advanced stages of clinical development. Currently, ocrelizumab, ofatumumab, and inebilizumab are licensed for treatment of MS and NMOSD, respectively. This review focuses on the current state of knowledge about the role of B lymphocytes in immune-mediated pathophysiology and its implications for the mode of action. To understand the significance of this breakthrough in the context of the current MS therapeutic armamentarium, this review more closely examines the clinical development of CD20 depletion and the pioneering contribution of rituximab. Phase 3 and the recently published postmarketing studies will be highlighted to better understand the relevant efficacy data and safety aspects of long-term B-cell depletion.


  • Open Access

    Targeting B cells to modify MS, NMOSD, and MOGAD

    by Jonas Graf, Jan Mares, Michael Barnett, Orhan Aktas, Philipp Albrecht, Scott S. Zamvil, Hans-Peter Hartung

    Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell–related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD) or are in advanced stages of clinical development. Currently, ocrelizumab and inebilizumab are licensed for treatment of MS and NMOSD, respectively. This part of the review focuses on monoclonal antibody B cell–depleting strategies in NMOSD and the emerging related myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G–associated disease (MOGAD). Case series and phase 2/3 studies in these inflammatory disorders are assessed. The safety profile of long-term B-cell depletion in MS, NMOSD, and MOGAD will be highlighted. Finally implications of the current coronavirus disease 2019 pandemic on the management of patients with these disorders and the use of B cell–depleting agents will be discussed.


  • Open Access

    Serum neurofilament light chain

    by Orhan Aktas, Alina Renner, André Huss, Melanie Filser, Sharon Baetge, Nathalie Stute, Marcia Gasis, Klaudia Lepka, Norbert Goebels, Makbule Senel, et al.

    Objective To explore the hypothesis that serum neurofilament light chain (sNfL) indicative of neuroaxonal damage may improve precise disease profiling with regard to cognition and neuropsychiatric symptoms, we analyzed potential associations of sNfL levels with cognitive test scores, fatigue, depression, and anxiety. Methods Patients with relapsing-remitting and secondary progressive MS (SPMS) underwent an elaborated assessment including MRI, various cognitive tests, and patient-reported outcomes. We determined sNfL levels by single molecule array (Simoa) assay. Relationships between sNfL, cognition, neuropsychiatric symptoms, and demographical data were analyzed using correlations, group comparisons, and regressions. Results In 45 clinically stable patients with MS (Expanded Disability Status Scale = 2.73 ± 1.12, disease duration = 10.03 ± 7.49 years), 40.0% were cognitively impaired. Mean sNfL levels were 16.02 ± 10.39 pg/mL, with higher levels in the SPMS subgroup (p = 0.038). sNfL levels did reliably link neither with the investigated cognitive and affective parameters nor with fatigue levels. The only relationship found in a small subgroup of patients with SPMS (n = 7) with visuospatial learning (r = −0.950, p = 0.001) and memory (r = −0.813; p = 0.026) disappeared when further controlling for age, educational level, and sex. Conclusions In patients with stable MS at less advanced disease stages, sNfL did not convincingly relate to cognitive performance, fatigue, depression, or anxiety and thus may not serve as a surrogate biomarker for neuropsychological status in such populations.


  • Author response: Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders

    by Marius Ringelstein, Jens Harmel, Hanna Zimmermann, Alexander U. Brandt, Friedemann Paul, Axel Haarmann, Mathias Buttmann, Martin W. Hümmert, Corinna Trebst, Christoph Schroeder, et al.